Abstract
No public abstract is available from the verified source records.
Rowan Gurney, Christine Girges, Nirosen Vijiaratnam, Dilan Athauda, Huw R. Morris, Thomas Foltynie
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes
2026
Genetic predictors of GLP1 receptor agonist weight loss and side effects
10.1038/s41586-026-10330-z · 2026
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
10.1016/s0140-6736(24)02808-3 · 2025
GLP1R gene expression and kidney disease progression
10.1001/jamanetworkopen.2024.40286 · 2024
The genotype-tissue expression (GTEx) project
10.1038/ng.2653 · 2013
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?
10.1002/sim.3639 · 2009
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
10.1093/brain/awad063 · 2023
No additional external references are available.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%